Want to join the conversation?
$BMY stated that Erbitux's rights were transferred to ImClone LLC, a wholly-owned subsidiary of $LLY, on Oct. 1, 2015 and hence the company no longer reports revenues. In 4Q15, total royalties for Erbitux in both the US and Japan were approx. $60MM and were recorded in other income.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.